Search Result

Results for "

Topo I Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (3) Akt (1) Antibiotic (4) Apoptosis (19) Bacterial (1) Bcl-2 Family (6) Biochemical Assay Reagents (1) Caspase (3) CDK (2) COX (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (3) Drug-Linker Conjugates for ADC (1) EGFR (1) Fungal (3) HDAC (1) IAP (1) IKK (1) Influenza Virus (3) Isotope-Labeled Compounds (1) Kinesin (1) MDM-2/p53 (2) MicroRNA (3) mTOR (1) NF-κB (1) PAK (1) PI3K (2) Prostaglandin Receptor (1) RAD51 (1) Reactive Oxygen Species (ROS) (6) Reference Standards (2) ROS Kinase (1) Topoisomerase (27)
By Research Areas:	Cancer (28) Infection (4) Inflammation/Immunology (1)

By Targets:

ADC Payload (3)

Akt (1)

Antibiotic (4)

Apoptosis (19)

Bacterial (1)

Bcl-2 Family (6)

Biochemical Assay Reagents (1)

Caspase (3)

CDK (2)

COX (1)

Cytochrome P450 (1)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (3)

Drug-Linker Conjugates for ADC (1)

EGFR (1)

Fungal (3)

HDAC (1)

IAP (1)

IKK (1)

Influenza Virus (3)

Isotope-Labeled Compounds (1)

Kinesin (1)

MDM-2/p53 (2)

MicroRNA (3)

mTOR (1)

NF-κB (1)

PAK (1)

PI3K (2)

Prostaglandin Receptor (1)

RAD51 (1)

Reactive Oxygen Species (ROS) (6)

Reference Standards (2)

ROS Kinase (1)

Topoisomerase (27)

By Research Areas:

Cancer (28)

Infection (4)

Inflammation/Immunology (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16560

Camptothecin 65+ Cited Publications Campathecin; (S)-(+)-Camptothecin; CPT	Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-128979

Deruxtecan analog 2	Drug-Linker Conjugates for ADC	Cancer
Deruxtecan analog 2 (example 9 P3) is a Deruxtecan (HY-13631E) analog. Deruxtecan analog 2 is a agent-linker conjugate composed of Camptothecin (HY-16560) and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC .

HY-49556

(S)-Benzyl 2-cyclopropyl-2-hydroxyacetate	Topoisomerase	Cancer
(S)-Benzyl 2-cyclopropyl-2-hydroxyacetate is an intermediate reactant in the synthesis of Camptothecin (HY-16560). Camptothecin is an inhibitor of the DNA topoisomerase Topo I, withIC₅₀=679 nM .

HY-16560S

Camptothecin-d5 Campathecin-d₅; (S)-(+)-Camptothecin-d₅; CPT-d₅	Isotope-Labeled Compounds Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-179520

XSJ151	Topoisomerase DNA/RNA Synthesis MDM-2/p53 Bcl-2 Family	Cancer
XSJ151 is a topoisomerase I inhibitor, stabilizing the DNA-Topo I covalent complex and inducing DNA double-strand breaks. XSJ151-induces DNA damage activates the p53-p21 signaling pathway, specifically regulating the expression of cyclins, leading to G2/M phase cell cycle arrest and disrupting the dynamic homeostasis of Bcl-2 family proteins, thereby triggering apoptosis in gastric cancer cells. XSJ151 can be used for the study of gastric cancer .

HY-170912

Topo I/II-IN-2	Topoisomerase Apoptosis ROS Kinase Cytochrome P450 Caspase Bcl-2 Family PI3K Akt mTOR	Cancer
Topo I/II-IN-2 (Compound 3g) is an inhibitor of Topo I and Topo II. Topo I/II-IN-2 inhibits NCI-H446 cells and NCI-H1048 cells with IC₅₀s of 1.30 μM and 1.42 μM, respectively. Topo I/II-IN-2 induces mitochondrial Apoptosis, mitochondrial dysfunction and activity generation. Topo I/II-IN-2 inhibits the PI3K/Akt/mTOR pathway. Topo I/II-IN-2 prevents SCLC (small cell lung cancer) cell proliferation, invasion, and migration in vitro. .

HY-162587

Fagopyrine	Topoisomerase	Cancer
Fagopyrine is a DNA topoisomerase I (Topo I) inhibitor. Fagopyrine is a photosensitizer that can be used in the study of tumors .

HY-162091

Topoisomerase I inhibitor 13	Topoisomerase	Cancer
Topoisomerase I inhibitor 13 (Compound G11) is a Topo I inhibitor that inhibits cancer cell proliferation. Topoisomerase I inhibitor 13 significantly inhibits tumor growth in vivo .

HY-150685

Topo I/COX-2-IN-1	Topoisomerase Prostaglandin Receptor Apoptosis	Inflammation/Immunology Cancer
Topo I/COX-2-IN-1 (1H-30) is a potential **Topo I/COX-2** inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC₅₀ value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity .

HY-16560R

Camptothecin (Standard) Campathecin (Standard); (S)-(+)-Camptothecin (Standard); CPT (Standard)	Reference Standards Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin (Standard) (Campathecin (Standard)) is the analytical standard of Camptothecin (HY-16560). This product is intended for research and analytical applications. Camptothecin (CPT), a kind of alkaloid, is a *DNA topoisomerase I (Topo* I)** inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

HY-145859

Topo I-IN-1	Topoisomerase Apoptosis Reactive Oxygen Species (ROS)	Cancer
Topo I-IN-1 (Compound 14d) is a potent Topo I inhibitor with antitumor activity and DNA intercalative capability. Topo I-IN-1 induces cell apoptosis .

HY-170580

Topo I/II-IN-1	Topoisomerase	Cancer
Topo I/II-IN-1 (compound 7t) is a potent Topo I and Topo II dual inhibitor. Topo I/II-IN-1 exhibits significant cytotoxicity against MCF-7 breast cancer cell line with an IC₅₀ of 7.45 μM .

HY-149002

Topoisomerase I/II inhibitor 4	Topoisomerase Apoptosis	Cancer
Topoisomerase I/II inhibitor 4 (compound F16) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 4 inhibits cell proliferation, invasion and migration and induces apoptosis. Topoisomerase I/II inhibitor 4 can be used for liver cancer research .

HY-150755

Topo I/COX-2-IN-2	Topoisomerase COX Apoptosis Reactive Oxygen Species (ROS)	Cancer
Topo I/COX-2-IN-2 (Compound W10) is a potent dual-target inhibitor of Topo I and COX-2 with IC₅₀ values of 0.90 μM and 2.31 μM, respectively. Topo I/COX-2-IN-2 induces cancer cell apoptosis through the mitochondrial pathway .

HY-158230

SN-398	Topoisomerase	Cancer
SN-398 is a derivative of Camptothecin (HY-158230), which is an antitumor drug. Acting by inhibiting mammalian DNA topoisomerase I (Topo I), stabilizing the Topo I-DNA complex prevents DNA rewiring to induce Topo I mediated DNA breaks. In Hela cell tests, SN-398 shows stronger antitumor activity than SN-38 (HY-13704) (IC₅₀=1.562 μM). SN-398 can be used to study the anti-proliferation and growth inhibition of Topo I in cancer cells .

HY-146504

Topoisomerase I/II inhibitor 3	Topoisomerase PI3K Apoptosis Reactive Oxygen Species (ROS)	Cancer
Topoisomerase I/II inhibitor 3 (compound 7) is a potent *topoisomerase I (Topo* I) and II (Topo II)** dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting PI3K/Akt/mTOR signaling pathway. Topoisomerase I/II inhibitor 3 can be used for liver cancer research .

HY-145867

EGFR-IN-45	Topoisomerase EGFR CDK Apoptosis	Cancer
EGFR-IN-45 is a potent epidermal growth factor receptor (EGFR) pan inhibitor, with IC₅₀s of 0.4 µM and 1.6 µM for EGFR and CDK2, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces apoptosis .

HY-156723

9-Chloromethyl-10-hydroxy-11-F-Camptothecin	Topoisomerase	Cancer
9-Chloromethyl-10-hydroxy-11-F-Camptothecin is a novel camptothecin derivatives. 9-Chloromethyl-10-hydroxy-11-F-Camptothecin is a *DNA topoisomerase I (Topo* I)** inhibitor, can be used in anticancer research .

HY-161970

XSJ05	Topoisomerase Apoptosis	Cancer
XSJ05 is a camptothecin (CPT) derivative that can inhibit topoisomerase I (Topo I) to exert anti-cancer activity. XSJ05 can trigger DNA double-strand breaks, leading to DNA damage. XSJ05 can inhibit the growth of colorectal cancer (CRC), arrest the cell cycle in G2/M phase, and induce apoptosis .

HY-174151

XSJ110	Topoisomerase Apoptosis	Cancer
XSJ110 is a potent irreversible topoisomerase I (Topo I) inhibitor with an IC₅₀ value of 0.133 μM. XSJ110 blocks DNA topoisomerization, induces DNA double-strand breaks, and triggers cell cycle arrest at G₀/G₁ phase, inducing tumor cell apoptosis. XSJ110 is promising for research of ampullary carcinoma (AC) .

HY-147698

ZLHQ-5f	CDK Topoisomerase Apoptosis	Cancer
ZLHQ-5f is a dual CDK2 and Topo I inhibitor with an IC₅₀ of 0.145 μM against CDK2/CycA2. ZLHQ-5f arrests the cell cycle in S-phase, triggers apoptosis in HCT116 cells, and has a good safety profile .

HY-141436R

Sucrosofate potassium (Standard) Sucrose octasulfate potassium (Standard)	Biochemical Assay Reagents Reference Standards	Cancer
Sucrosofate (potassium) (Standard) is the analytical standard of Sucrosofate (potassium). This product is intended for research and analytical applications. Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .

HY-178738

GC-072	Antibiotic Bacterial Topoisomerase DNA/RNA Synthesis	Infection
GC-072 is an orally active, 4-oxoquinolizine antibiotic that selectively inhibits bacterial DNA gyrase and Topo IV enzymes. GC-072 does not inhibit human topoisomerases I and II. GC-072 demonstrates strong antimicrobial activity against various bacterial strains, including Gram-positive, Gram-negative, and resistant bacteria. GC-072 also exhibits bactericidal activity against Burkholderia pseudomallei both extracellularly and intracellularly, leading to dose-dependent survival in mice exposed to lethal inhalational models of B. pseudomallei infection. GC-072 can be used for the research of melioidosis .

HY-181018

Topo I/DDX5-IN-1	Topoisomerase PAK Bcl-2 Family IAP Reactive Oxygen Species (ROS) Apoptosis	Cancer
Topo I/DDX5-IN-1 (Compound A10) is a Topo I and DDX5 inhibitor. Topo I/DDX5-IN-1 inhibits Topo I activity, binds to DDX5, and suppresses DDX5 function. Topo I/DDX5-IN-1 increases expression of γ-H2AX and p21, suppresses the expression of antiapoptotic proteins (Bcl-2 and XIAP), stimulates ROS generation, and triggers Apoptosis. Topo I/DDX5-IN-1 exhibits anticancer activity against pancreatic cancer, non-small cell lung cancer, skin cancer, and colorectal cancer .

HY-183330

Topo I/II-IN-3	Topoisomerase Reactive Oxygen Species (ROS) Apoptosis MDM-2/p53 Caspase Bcl-2 Family	Cancer
Topo I/II-IN-3 is a dual inhibitor of topoisomerase I/II (topoisomerase I/II), with an IC₅₀ of 8.99 μM against Topo I and an IC₅₀ of 26.92 μM against Topo II. Topo I/II-IN-3 induces DNA damage, elevates intracellular ROS levels, activates the mitochondrial apoptosis pathway, and exerts cytotoxicity against cancer cells. Topo I/II-IN-3 upregulates the expression of γ-H2AX, p53, activated caspase-9, Bax and activated caspase-3, while downregulating the expression of Bcl-2. Topo I/II-IN-3 can be used in research related to breast cancer, liver cancer and gastric cancer .

HY-182748

NL-26	Topoisomerase DNA/RNA Synthesis Apoptosis	Cancer
NL-26 is a Topoisomerase I inhibitor. NL-26 stabilizes the covalent Topoisomerase I (Topo I)-DNA complex, prevents DNA religation and triggers the DNA damage response. NL-26 induces G₂/M cell cycle arrest and apoptosis in cancer cells. NL-26 can be used for the research of colorectal cancer .

HY-181836

IKKβ-IN-6	IKK Topoisomerase Apoptosis NF-κB Reactive Oxygen Species (ROS) Bcl-2 Family	Cancer
IKKβ-IN-6 is an antitumor agent. IKKβ-IN-6 inhibits IKKβ (IC₅₀: 18.24 μM), thereby suppressing the phosphorylation of p65 and IκBα, blocking the nuclear translocation of p65, and subsequently regulating genes controlled by NF-κB. IKKβ-IN-6 also targets topoisomerase I (Topo I), induces DNA damage, ROS accumulation, loss of mitochondrial membrane potential, and S-phase arrest. IKKβ-IN-6 is applicable to related research on colorectal cancer .

HY-181694

SeSA-HCPT	Topoisomerase HDAC Apoptosis Kinesin RAD51	Cancer
SeSA-HCPT is an orally active dual-target inhibitor integrating Topo I and HDAC inhibition. SeSA-HCPT induces potent DNA damage, apoptosis, S-phase arrest in prostate cancer cells. SeSA-HCPT inhibits cancer cells proliferation and migration. SeSA-HCPT impairs homologous recombination by suppressing KIF4A-RAD51 signaling. SeSA-HCPT markedly inhibits CRPC tumor growth with minimal systemic toxicity .

HY-N18184

Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside)	Others	Others
Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside) (Compound 5) is a flavonoid. Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside) can be isolated from the aerial parts of C. texanus. Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside) does not inhibit Topo I .

HY-182760

MN33-63	DNA Alkylator/Crosslinker Bcl-2 Family Caspase Apoptosis Topoisomerase	Cancer
MN33-63 is a Bcl-2 inhibitor, caspase-3 activator and DNA crosslinker with broad-spectrum anticancer activity. MN33-63 improves the water solubility of SN-38 (HY-13704), inhibits tumor growth and proliferation in a dose-dependent manner, and causes no obvious toxicity. MN33-63 relieves the inhibition of the mitochondrial apoptotic pathway, initiates the apoptosis program, inhibits Topo I activity, and promotes its degradation via the ubiquitin-proteasome and autophagy-lysosome pathways. MN33-63 induces DNA crosslinking, G2/M cell cycle arrest, inhibition of cancer cell migration, and cancer cell apoptosis through the mitochondrial pathway. MN33-63 can be used in the research of colorectal cancer, cervical cancer, hepatocellular carcinoma, lung adenocarcinoma and gastric cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16560

Camptothecin 65+ Cited Publications Campathecin; (S)-(+)-Camptothecin; CPT	Infection Alkaloids Classification of Application Fields Quinoline Alkaloids Camptotheca acuminata Decne. Nyssaceae Plants Disease Research Fields	Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-16560R

Camptothecin (Standard) Campathecin (Standard); (S)-(+)-Camptothecin (Standard); CPT (Standard)	Alkaloids Structural Classification Quinoline Alkaloids Camptotheca acuminata Decne. Nyssaceae Plants	Reference Standards Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic
Camptothecin (Standard) (Campathecin (Standard)) is the analytical standard of Camptothecin (HY-16560). This product is intended for research and analytical applications. Camptothecin (CPT), a kind of alkaloid, is a *DNA topoisomerase I (Topo* I)** inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

HY-N18184

Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside)	Structural Classification Flavonoids Flavones Quercus mongolica Fischer ex Ledebour Euphorbiaceae Plants Source Classification	Others
Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside) (Compound 5) is a flavonoid. Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside) can be isolated from the aerial parts of C. texanus. Naringenin-7-O-(3''-E-p-coumaroyl-β-D-glucopyranoside) does not inhibit Topo I .

Cat. No.	Product Name	Chemical Structure

HY-16560S

Camptothecin-d5
Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

Camptothecin-d5

Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks